ADULT AMBULATORY INFUSION ORDER
Epoetin alfa-epbx (RETCRIT)
Injection Maintenance for Oncology Patients

Weight: ___________kg  Height: ___________cm

Allergies: __________________________________________

Diagnosis Code: __________________________________________

Treatment Start Date: ________________  Patient to follow up with provider on date: ________________

**This plan will expire after 365 days at which time a new order will need to be placed**
**This order set is for MAINTENANCE DOSING ONLY. Patients should have received first dose via the INITIATION order set with either chemotherapy-induced anemia or myelodysplastic syndrome selected as indications**

INDICATION: *(Must check one)*
- □ Chemotherapy-induced anemia
- □ Symptomatic anemia associated with myelodysplastic syndrome (MDS)

GUIDELINES FOR ORDERING
1. Send FACE SHEET and H&P or most recent chart note.
2. OHSU’s formulary erythropoiesis stimulating agent (ESA) is darbepoetin alfa (ARANESP). All orders for epoetin alfa-epbx (RETCRIT) will be converted to darbepoetin alfa using equivalent therapeutic interchange dosing listed in the table below. Providers who prefer to use epoetin alfa-epbx must specify a reason for its use. REASON FOR EPOETIN USE: __________________________________________

3. Patients receiving concurrent treatment with Iron Sucrose (VENOFER) and/or Vitamin B12 cannot receive ESA treatment on the same day. Patients may be on prophylactic oral iron supplementation concurrent with ESA treatment as long as supplementation for the prevention of iron deficiency is necessary due to ESA therapy alone.

4. Serum ferritin and transferrin saturation (TSAT) must be performed every month during initial (ESA) treatment and at least every 3 months during stable ESA treatment (serum ferritin greater than 100 ng/mL, and TSAT greater than or equal to 20%). Therapy with epoetin alfa-epbx may continue only if hemoglobin DOES NOT equal or exceed 11 g/dL.

5. For patients with chemotherapy-induced anemia: The medical record must document the provider’s rationale for determining the anemia is “chemotherapy-induced.” Anemia must be secondary to myelosuppressive anticancer chemotherapy in solid tumors, multiple myeloma, lymphoma, or lymphocytic leukemia. Treatment should be limited to the 8 weeks following myelosuppressive chemotherapy.

6. For patients with symptomatic anemia from MDS: The patient must be symptomatic and his/her life expectancy must be >3 months. The medical record must display documentation that a bone marrow biopsy has been reviewed by a provider and is consistent with the diagnosis of MDS. The marrow blast count must be <5%
LABS:
- Hemoglobin & Hematocrit, Routine, ONCE, (weekly) or every _____ (visit)(days)(weeks)(months) – Circle One
- CMP, Routine, ONCE, (weekly) or every __________ (visit)(days)(weeks)(months) – Circle One
- Ferritin (serum), Routine, ONCE, every 12 weeks
- Iron and TIBC (serum), Routine, ONCE, every 12 weeks
- Labs already drawn. Date: __________ (Must have been drawn at least 14 days after the last dose)

NURSING ORDERS:
1. Patients receiving concurrent treatment with Iron Sucrose (VENOFER) and/or Vitamin B12 cannot receive ESA treatment on the same day.
2. TREATMENT PARAMETERS – Hold treatment and call provider if hemoglobin is greater than or equal to 11, serum ferritin is less than or equal to 100 ng/mL, transferrin saturation is less than 20% or if blood pressure is greater than 180 systolic or 100 diastolic
3. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

OTHER:

Conversion from epoetin alfa-epbx (RETACRIT) to darbepoetin alfa (ARANESP): Initial adult dosing

<table>
<thead>
<tr>
<th>Epoetin alfa-epbx dose (units/week)</th>
<th>Darbepoetin alfa dose (mcg/week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1500</td>
<td>6.25</td>
</tr>
<tr>
<td>1500-2499</td>
<td>6.25</td>
</tr>
<tr>
<td>2500-4999</td>
<td>12.5</td>
</tr>
<tr>
<td>5000-10,999</td>
<td>25</td>
</tr>
<tr>
<td>11,000-17,999</td>
<td>40</td>
</tr>
<tr>
<td>18,000-33,999</td>
<td>60</td>
</tr>
<tr>
<td>34,000-89,999</td>
<td>100</td>
</tr>
<tr>
<td>≥90,000</td>
<td>200</td>
</tr>
</tbody>
</table>

In patients receiving epoetin alfa-epbx 2-3 times weekly, darbepoetin should be given once weekly. If epoetin is administered once weekly, darbepoetin should be given once every 2 weeks. Darbepoetin dosing every 2 weeks should be determined by adding the 2 weekly epoetin alfa-epbx doses, then convert to appropriate corresponding darbepoetin dose. Doses should be titrated to hemoglobin response thereafter.
MEDICATIONS:

- epoetin alfa-epbx (RETCRIT), subcutaneous, ONCE
  
  *Pharmacist will round dose to nearest vial size if within 10% of original dose during verification*

Weight based regimen:

- Dose
  - □ _________ units/kg = _________ units

- Interval:
  - □ Weekly x _________ weeks
  - □ _________ times per week x _________ weeks

Fixed dose regimens:

- Dose:
  - □ 2,000 units
  - □ 3,000 units
  - □ 4,000 units
  - □ 10,000 units
  - □ 20,000 units
  - □ 40,000 units

- Interval:
  - □ Weekly x _________ weeks
  - □ _________ times per week x _________ weeks
Epoetin alfa-epbx (RETACRIT) Injection Maintenance for Oncology Patients

By signing below, I represent the following:
I am responsible for the care of the patient (who is identified at the top of this form);
I hold an active, unrestricted license to practice medicine in:  □ Oregon  □  
(check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);

My physician license Number is #  (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: __________________________  Date/Time: __________________________
Printed Name: __________________________  Phone: __________  Fax: __________

OLC Central Intake Nurse:
Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient’s preferred clinic location:

□ Beaverton  
OHSU Knight Cancer Institute  
15700 SW Greystone Court  
Beaverton, OR 97006  
Phone number: 971-262-9000  
Fax number: 503-346-8058

□ NW Portland  
Legacy Good Samaritan campus  
Medical Office Building 3, Suite 150  
1130 NW 22nd Ave.  
Portland, OR 97210  
Phone number: 971-262-9600  
Fax number: 503-346-8058

□ Gresham  
Legacy Mount Hood campus  
Medical Office Building 3, Suite 140  
24988 SE Stark  
Gresham, OR 97030  
Phone number: 971-262-9500  
Fax number: 503-346-8058

□ Tualatin  
Legacy Meridian Park campus  
Medical Office Building 2, Suite 140  
19260 SW 65th Ave.  
Tualatin, OR 97062  
Phone number: 971-262-9700  
Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders